- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01316458
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany
- Novartis Investigative Site
-
Berlin, Germany
- Novarts Investigative Site
-
Bonn, Germany
- Novartis Investigative Site
-
Borken, Germany
- Novartis Investigative Site
-
Darmstadt, Germany
- Novartis Investigative Site
-
Fürth, Germany
- Novartis Investigative Site
-
Gardelegen, Germany
- Novartis Investigative Site
-
Hamburg, Germany
- Novarts Investigative Site
-
Köln, Germany
- Novartis Investigative Site
-
Marburg, Germany
- Novartis Investigative Site
-
Ulm, Germany
- Novartis Investigative Site
-
Wesel, Germany
- Novartis Investigative Site
-
Wuppertal, Germany
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- who are 18 years of age or older.
- who have undergone radical prostatectomy within 2 years prior to PSA progression .
- exhibiting two consecutive rises in PSA levels relative to a previous reference value, separated by 14 days.
The first measurement must occur 14 days after the reference value und must be at least 20% above the reference value. The reference value must be at least 0.4 ng/ml. The second confirmatory measurement taken 14 days after the first measurement must be greater than the first measurement.
- with a Karnofsky Performance Score (KPS) greater than or equal to 90 (Appendix 5).
- with the following hematologic lab values: ANC greater than or equal to 1500/mm3, Hgb greater than or equal to 10g/dL, PLT greater than or equal to 100x109/L.
- with the following biochemistry lab values: total bilirubin < 1.5 ULN, SGOT, SGPT less than or equal to 2.5 ULN, serum creatinine less than or equal to 1.5 ULN.
- willing to employ an effective barrier method of contraception during the study duration and for 3 months following discontinuation of study drug (for patients of reproductive potential).
- with a life expectancy of > 6 months.
- who have provided written informed consent pursuant to local regulatory requirements prior to initiation of any study procedure.
with a Gleason Score > 6 in the prostatectomy specimen
Exclusion Criteria:
- with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer, unless written approval is obtained by the sponsor.
- with prior hormonal therapy
- who require therapy with warfarin or analgesics of the morphine class or higher (see Section 3.4.4).
- with a known diagnosis of HIV, hepatitis B, or hepatitis C infection.
- who have had a major surgery within 2 weeks prior to study entry.
- with severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency (NYHA III or IV, see Appendix 2), uncontrolled diabetes, chronic hepatic or renal disease, and active uncontrolled infection.
- with a history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits.
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: imatinib mesylate
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.
Time Frame: 2 - 4 weeks
|
2 - 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
investigate the time to sustained biochemical response under the treatment of Glivec® in this patient population
Time Frame: continuous
|
continuous
|
investigate duration of biochemical sustained response under the treatment with Glivec® in this patient population.
Time Frame: continuous
|
continuous
|
To assess the response rates: number of patients with complete, partial and minor biochemical response and stable PSA
Time Frame: continuous
|
continuous
|
To assess the time to clinical progression of this patient population treated with Glivec® at this dose and schedule.
Time Frame: continuous
|
continuous
|
To descriptively characterize the safety and tolerability of Glivec® administered at this dose and schedule to this patient population.
Time Frame: continuous
|
continuous
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSTI571BDE15
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urogenital Neoplasms
-
Assiut UniversityRecruitingGenitourinary Neoplasms | Neoplasms, GenitourinaryEgypt
-
Changhai HospitalUTC Therapeutics Inc.RecruitingCD70-positive Advanced Urologic NeoplasmsChina
-
Zealand University HospitalRecruiting
-
Merck Sharp & Dohme LLCRecruitingUrinary Bladder NeoplasmsUnited States, Australia, Czechia, Estonia, France, Guatemala, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Turkey, Ukraine, United Kingdom, Denmark, ... and more
-
The University of Texas Health Science Center at...TerminatedUrinary Bladder NeoplasmsUnited States
-
University of California, DavisActive, not recruiting
-
Lahey ClinicActive, not recruiting
-
Centre Hospitalier Universitaire de BesanconNot yet recruiting
-
Huashan HospitalNot yet recruiting
Clinical Trials on STI571 (Glivec®)
-
Novartis PharmaceuticalsCompletedAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Philadelphia Positive Chronic Myeloid LeukemiaUnited States, Germany, United Kingdom, France, Italy
-
Novartis PharmaceuticalsTerminatedMyelogenous LeukemiaUnited States, Germany, Belgium, Italy, Spain, Korea, Republic of, Brazil, Japan, Australia, Czech Republic
-
Novartis PharmaceuticalsCompletedSystemic Sclerosis, SclerodermaUnited States, Germany, Italy, Switzerland, United Kingdom
-
Novartis PharmaceuticalsCompletedPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia
-
Novartis PharmaceuticalsTerminatedChronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)Russian Federation
-
Novartis PharmaceuticalsCompletedGastrointestinal Stromal TumorsJapan
-
Novartis PharmaceuticalsCompletedGastrointestinal Stromal TumorsSaudi Arabia, Taiwan, Turkey, Egypt, Thailand, Russian Federation, South Africa, Lebanon, India, Tunisia, Algeria, Jordan
-
Novartis PharmaceuticalsCompletedGastrointestinal Stromal Tumor (GIST)China, South Africa, United States, France, Italy, United Kingdom, Germany, Taiwan, Turkey, Canada, Egypt, Singapore, Argentina, Austria, Poland, Russian Federation, Spain, Sweden, Thailand, Korea, Republic of, Bulgaria, Denmark, Japan and more
-
Novartis PharmaceuticalsTerminatedLeukemia, Myeloid, Chronic PhaseUnited States, Argentina, Italy, Canada, Australia, Brazil
-
Novartis PharmaceuticalsCompleted